Just weeks ago, the FDA approved the first ever medicine made from a derivative of marijuana, a drug from GW Pharmaceuticals for a rare form of epilepsy. Yet competition already looms from San Diego’s Zogenix, thanks to new data the Emeryville, CA, company reports this morning.
Zogenix (NASDAQ: ZGNX) said that its experimental drug ZX008 succeeded in the second of two Phase 3 trials in patients with Dravet Syndrome. The 43 patients on ZX008 had an average of 54.7 percent fewer convulsive seizures, per month, than the 44 on a placebo. The median reduction in seizures per month for ZX008… Read more »
UNDERWRITERS AND PARTNERS